Cargando…
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
BACKGROUND: Breast cancer is a heterogeneous disease at the clinical and molecular level. In this study we integrate classifications extracted from five different molecular levels in order to identify integrated subtypes. METHODS: Tumor tissue from 425 patients with primary breast cancer from the Os...
Autores principales: | Aure, Miriam Ragle, Vitelli, Valeria, Jernström, Sandra, Kumar, Surendra, Krohn, Marit, Due, Eldri U., Haukaas, Tonje Husby, Leivonen, Suvi-Katri, Vollan, Hans Kristian Moen, Lüders, Torben, Rødland, Einar, Vaske, Charles J., Zhao, Wei, Møller, Elen K., Nord, Silje, Giskeødegård, Guro F., Bathen, Tone Frost, Caldas, Carlos, Tramm, Trine, Alsner, Jan, Overgaard, Jens, Geisler, Jürgen, Bukholm, Ida R. K., Naume, Bjørn, Schlichting, Ellen, Sauer, Torill, Mills, Gordon B., Kåresen, Rolf, Mælandsmo, Gunhild M., Lingjærde, Ole Christian, Frigessi, Arnoldo, Kristensen, Vessela N., Børresen-Dale, Anne-Lise, Sahlberg, Kristine K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372339/ https://www.ncbi.nlm.nih.gov/pubmed/28356166 http://dx.doi.org/10.1186/s13058-017-0812-y |
Ejemplares similares
-
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
por: Aure, Miriam Ragle, et al.
Publicado: (2015) -
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
por: Haukaas, Tonje H., et al.
Publicado: (2016) -
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
por: Tinholt, Mari, et al.
Publicado: (2015) -
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
por: Jernström, Sandra, et al.
Publicado: (2017) -
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
por: Normann, Lisa Svartdal, et al.
Publicado: (2021)